Rheumatoid arthritis
Adjunct
Gamma-linolenic acid (GLA) from borage or evening primrose oil at 1.4–2.8 g/day delivered modest reductions in pain and morning stiffness in small randomised trials in rheumatoid arthritis. The Cochrane review CD002948 (2011) rated the effect as weak, inconsistent, and insufficient to replace disease-modifying therapy. Current 2023 and SER 2024 guidelines build treatment on methotrexate, biologics, and targeted JAK inhibitors. GLA can be considered as an adjunct to mainstay therapy after agreement with a rheumatologist, never as a substitute.